Rituximab is a monoclonal antibody which is developed against CD 20 antigen, increasingly used nowadays. While it is used in the treament of the diseases such as lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, transverse myelitis; can also cause interstitial lung disease. A 59 year old female patient who has been followed up with the disease of transverse myelitis and receiving rituximab therapy, applied to the emergency department with labored breath, cough, and fever after drug use. As a result of clinical and radiological evaluations, the patient has diagnosed as drug-related interstitial lung disease. One month after the termination of rituximab therapy and the start of methylprednisolone, the patient’s clinical and radiological findings improved. In conclusion, while investigating the primary cause in interstitial lung disease, the drugs used by the patient should be questioned in this respect and it should be kept in mind that many other drugs such as rituximab can be involved in the etiology.